• 1. Nitrogen positional scanning in tetramines active against HIV-1 as potential CXCR4 inhibitors
  Raimon Puig de la Bellacasa,Albert Gibert,Jesús M. Planesas,Laia Ros-Blanco,Xavier Batllori,Roger Badía,Bonaventura Clotet,José Esté,Jordi Teixidó,José I. Borrell Org. Biomol. Chem. 2016 14 1455
• 2. Binary reducing agents containing dichloroindium hydride for the selective, partial, or tandem reductions of bifunctional compounds consisting of halo-nitriles, halo-esters and halo-carboxylic acids
  Rachel Snelling,Jaime Z. Saavedra,Panathda Bayrasy,Yashar Abdollahian,Bakthan Singaram Org. Chem. Front. 2015 2 133
• 3. Novel pyridinium oximes: synthesis, molecular docking and in vitro reactivation studies
  Pooja,S. Aggarwal,A. K. Tiwari,V. Kumar,R. Pratap,G. Singh,A. K. Mishra RSC Adv. 2015 5 23471
• 4. Structure-guided synthesis of a protein-based fluorescent sensor for alkyl halides
  Myeong-Gyun Kang,Hakbong Lee,Beom Ho Kim,Yerkin Dunbayev,Jeong Kon Seo,Changwook Lee,Hyun-Woo Rhee Chem. Commun. 2017 53 9226

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzyl halides Benzyl bromides

Introduction to 4-(Bromomethyl)phenylacetic Acid (CAS No. 13737-36-5)

4-(Bromomethyl)phenylacetic acid, with the chemical formula C₈H₇BrO₂, is a versatile intermediate in organic synthesis and pharmaceutical research. This compound, identified by its CAS number CAS No. 13737-36-5, has garnered significant attention due to its utility in the development of novel therapeutic agents and fine chemicals. The presence of both a bromomethyl group and a phenylacetic acid moiety makes it a valuable building block for constructing more complex molecules.

The bromomethyl group is a reactive handle that allows for further functionalization through nucleophilic substitution reactions, enabling the introduction of various pharmacophores. On the other hand, the phenylacetic acid moiety is known for its role in biological systems, particularly as a precursor to neurotransmitters and other bioactive molecules. This dual functionality makes 4-(Bromomethyl)phenylacetic acid an attractive candidate for medicinal chemists seeking to develop new drugs.

In recent years, there has been a surge in research focused on the development of small-molecule inhibitors targeting various disease pathways. One notable area of interest is the inhibition of enzymes involved in cancer metabolism. Studies have shown that phenylacetic acid derivatives can modulate metabolic pathways such as the tricarboxylic acid (TCA) cycle and fatty acid oxidation, which are often dysregulated in cancer cells. The bromomethyl group in 4-(Bromomethyl)phenylacetic acid provides a convenient entry point for designing such inhibitors by allowing selective attachment of pharmacophores that can interact with specific enzyme targets.

Another promising application of 4-(Bromomethyl)phenylacetic acid lies in the field of neurodegenerative diseases. Research indicates that phenylacetic acid derivatives can exhibit neuroprotective properties by interacting with neurotransmitter systems and reducing oxidative stress. For instance, studies have demonstrated that certain phenylacetic acid analogs can attenuate neuroinflammation and protect against neuronal damage in models of Alzheimer's and Parkinson's diseases. The reactivity of the bromomethyl group allows for the customization of these derivatives to optimize their pharmacological profiles.

The synthesis of 4-(Bromomethyl)phenylacetic acid typically involves bromination of phenylacetic acid or related precursors. Advanced synthetic techniques, such as palladium-catalyzed cross-coupling reactions, have also been employed to introduce the bromomethyl group with high selectivity and yield. These methods are crucial for ensuring the purity and functionality of the final product, which is essential for downstream applications in drug development.

In conclusion, 4-(Bromomethyl)phenylacetic acid (CAS No. 13737-36-5) is a multifunctional compound with significant potential in pharmaceutical research. Its unique structure combines reactivity with biological relevance, making it a valuable tool for developing new therapeutic agents targeting various diseases. As research continues to uncover new applications for this compound, its importance in medicinal chemistry is likely to grow further.

• 89-51-0(2-(carboxymethyl)benzoic acid)
• 90-64-2(Mandelic acid)
• 101-97-3(Ethyl phenylacetate)
• 102-13-6(Isobutyl 2-phenylacetate)
• 102-16-9(Benzyl phenylacetate)
• 102-19-2(Isopentyl 2-phenylacetate)
• 101-41-7(Methyl phenylacetate)
• 102-20-5(2-Phenylethyl 2-Phenylacetate)
• 86-87-3(1-Naphthylacetic acid)
• 90-27-7(2-Phenylbutyric acid)